Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: TOGETHER-PsA Trial
Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A
Summary
In the TOGETHER-PsA trial (n=271), combining tirzepatide with ixekizumab achieved ACR50 + ≥10% weight loss in 31.7% of patients versus 0.8% with ixekizumab alone (p<0.001) at 36 weeks. The combination also significantly improved ACR50 (33.5% vs 20.4%), minimal disease activity, and patient-reported outcomes including disability and fatigue.
Clinical Significance
This trial provides the first evidence that adding tirzepatide to biologic therapy in psoriatic arthritis patients with obesity delivers dual metabolic and rheumatologic benefits. It supports a paradigm shift toward integrated inflammatory-metabolic treatment approaches, as 72-82% of PsA patients have overweight/obesity.
Související výzkum
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: SURPASS-CVOT
In a post hoc analysis of the landmark SURPASS-CVOT trial (n=13,165), tirzepatide demonstrated a 16%…
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Tirzepatide/Semaglutide Weight Loss Intervention in Patients With Endometrial Cancer and Obesity
Memorial Sloan Kettering is conducting a pilot study evaluating tirzepatide (with semaglutide as alt…